Chloroquine and Hydroxychloroquine in the Treatment of COVID-19: the Never-ending Story

Overview

Journal Appl Microbiol Biotechnol

Specialties Biomedical Engineering
Biotechnology
Microbiology

Date 2021 Jan 30

PMID 33515285

Citations 44

Authors

Amin Gasmi

Massimiliano Peana

Sadaf Noor

Roman Lysiuk

Alain Menzel

Asma Gasmi Benahmed

Geir Bjorklund

Affiliations

Soon will be listed here.

Abstract

The anti-malarial drugs chloroquine (CQ) and hydroxychloroquine (HCQ) have been suggested as promising agents against the new coronavirus SARS-CoV-2 that induces COVID-19 and as a possible therapy for shortening the duration of the viral disease. The antiviral effects of CQ and HCQ have been demonstrated in vitro due to their ability to block viruses like coronavirus SARS in cell culture. CQ and HCQ have been proposed to reduce immune reactions to infectious agents, inhibit pneumonia exacerbation, and improve lung imaging investigations. CQ analogs have also revealed the anti-inflammatory and immunomodulatory effects in treating viral infections and related ailments. There was, moreover, convincing evidence from early trials in China about the efficacy of CQ and HCQ in the anti-COVID-19 procedure. Since then, research and studies have been massive to ascertain these drugs' efficacy and safety in treating the viral disease. In the present review, we construct a synopsis of the main properties and current data concerning the metabolism of CQ/HCQ, which were the basis of assessing their potential therapeutic roles against the new coronavirus infection. The effective role of QC and HCQ in the prophylaxis and therapy of COVID-19 infection is discussed in light of the latest international medical-scientific research results. KEY POINTS: • Data concerning metabolism and properties of CQ/HCQ are discussed. • The efficacy of CQ/HCQ against COVID-19 has been the subject of contradictory results. • CQ/HCQ has little or no effect in reducing mortality in SARS-CoV-2-affected patients.

Citing Articles

Hydroxychloroquine: A double‑edged sword (Review).

Huo R, Wei C, Yang Y, Lin J, Huang X Mol Med Rep. 2025; 31(4).

PMID: 39981928 PMC: 11868775. DOI: 10.3892/mmr.2025.13467.

Efficacy and Safety of Antimalarial as Repurposing Drug for COVID-19 Following Retraction of Chloroquine and Hydroxychloroquine.

Latarissa I, Khairinisa M, Iftinan G, Meiliana A, Sormin I, Barliana M Clin Pharmacol. 2025; 17():1-11.

PMID: 39845335 PMC: 11748038. DOI: 10.2147/CPAA.S493750.

Preclinical and Clinical Investigations of Potential Drugs and Vaccines for COVID-19 Therapy: A Comprehensive Review With Recent Update.

Mia M, Howlader M, Akter F, Hossain M Clin Pathol. 2024; 17:2632010X241263054.

PMID: 39070952 PMC: 11282570. DOI: 10.1177/2632010X241263054.

Inhibition of endocytic uptake of severe acute respiratory syndrome coronavirus 2 and endo-lysosomal acidification by diphenoxylate.

Shin J, Jang Y, Kim D, Jung E, Lee M, Kim B Antimicrob Agents Chemother. 2024; 68(6):e0034124.

PMID: 38742905 PMC: 11620506. DOI: 10.1128/aac.00341-24.

Coordination chemistry suggests that independently observed benefits of metformin and Zn against COVID-19 are not independent.

Lockwood T Biometals. 2024; 37(4):983-1022.

PMID: 38578560 PMC: 11255062. DOI: 10.1007/s10534-024-00590-5.

References

Yang Z, Huang Y, Ganesh L, Leung K, Kong W, Schwartz O . pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol. 2004; 78(11):5642-50. PMC: 415834. DOI: 10.1128/JVI.78.11.5642-5650.2004. View

Emerole G, Thabrew M . Changes in some rat hepatic microsomal components induced by prolonged administration of chloroquine. Biochem Pharmacol. 1983; 32(20):3005-9. DOI: 10.1016/0006-2952(83)90241-1. View

van den Borne B, Dijkmans B, de Rooij H, le Cessie S, Verweij C . Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. J Rheumatol. 1997; 24(1):55-60. View

Colson P, Rolain J, Lagier J, Brouqui P, Raoult D . Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020; 55(4):105932. PMC: 7135139. DOI: 10.1016/j.ijantimicag.2020.105932. View

Al-Bari M . Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother. 2015; 70(6):1608-21. PMC: 7537707. DOI: 10.1093/jac/dkv018. View

Catteau L, Dauby N, Montourcy M, Bottieau E, Hautekiet J, Goetghebeur E . Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants. Int J Antimicrob Agents. 2020; 56(4):106144. PMC: 7444610. DOI: 10.1016/j.ijantimicag.2020.106144. View

Tracey K, Cerami A . Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med. 1994; 45:491-503. DOI: 10.1146/annurev.med.45.1.491. View

Vessoni A, Quinet A, de Andrade-Lima L, Martins D, Garcia C, Rocha C . Chloroquine-induced glioma cells death is associated with mitochondrial membrane potential loss, but not oxidative stress. Free Radic Biol Med. 2015; 90:91-100. DOI: 10.1016/j.freeradbiomed.2015.11.008. View

. Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study. Eur J Intern Med. 2020; 82:38-47. PMC: 7446618. DOI: 10.1016/j.ejim.2020.08.019. View

10.

Katz S, Russell A . Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action. Curr Opin Rheumatol. 2011; 23(3):278-81. DOI: 10.1097/BOR.0b013e32834456bf. View

11.

Cassera M, Zhang Y, Hazleton K, Schramm V . Purine and pyrimidine pathways as targets in Plasmodium falciparum. Curr Top Med Chem. 2011; 11(16):2103-15. PMC: 3319363. DOI: 10.2174/156802611796575948. View

12.

Vigerust D, McCullers J . Chloroquine is effective against influenza A virus in vitro but not in vivo. Influenza Other Respir Viruses. 2009; 1(5-6):189-92. PMC: 4941887. DOI: 10.1111/j.1750-2659.2007.00027.x. View

13.

Helal G, Gad M, Abd-Ellah M, Eid M . Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients. J Med Virol. 2016; 88(12):2170-2178. PMC: 7167065. DOI: 10.1002/jmv.24575. View

14.

Wessels I, Rolles B, Rink L . The Potential Impact of Zinc Supplementation on COVID-19 Pathogenesis. Front Immunol. 2020; 11:1712. PMC: 7365891. DOI: 10.3389/fimmu.2020.01712. View

15.

Lazarczyk M, Favre M . Role of Zn2+ ions in host-virus interactions. J Virol. 2008; 82(23):11486-94. PMC: 2583646. DOI: 10.1128/JVI.01314-08. View

16.

Slater A, Cerami A . Inhibition by chloroquine of a novel haem polymerase enzyme activity in malaria trophozoites. Nature. 1992; 355(6356):167-9. DOI: 10.1038/355167a0. View

17.

Zheng J, Zhang X, Yu H, Taggart J, Ding W . Zinc at cytotoxic concentrations affects posttranscriptional events of gene expression in cancer cells. Cell Physiol Biochem. 2012; 29(1-2):181-8. PMC: 3711771. DOI: 10.1159/000337599. View

18.

Ektorp E . Death threats after a trial on chloroquine for COVID-19. Lancet Infect Dis. 2020; 20(6):661. PMC: 7255234. DOI: 10.1016/S1473-3099(20)30383-2. View

19.

Chowdhury M, Rathod J, Gernsheimer J . A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19. Acad Emerg Med. 2020; 27(6):493-504. PMC: 7267507. DOI: 10.1111/acem.14005. View

20.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M . Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3):269-271. PMC: 7054408. DOI: 10.1038/s41422-020-0282-0. View